Xiaoli Wei

3.4k total citations · 1 hit paper
61 papers, 2.0k citations indexed

About

Xiaoli Wei is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xiaoli Wei has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Xiaoli Wei's work include Cancer Immunotherapy and Biomarkers (15 papers), Gastric Cancer Management and Outcomes (10 papers) and HER2/EGFR in Cancer Research (6 papers). Xiaoli Wei is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Gastric Cancer Management and Outcomes (10 papers) and HER2/EGFR in Cancer Research (6 papers). Xiaoli Wei collaborates with scholars based in China, United States and South Korea. Xiaoli Wei's co-authors include Liangfang Zhang, Weiwei Gao, Ying Man, Ronnie H. Fang, Diana Dehaini, Pavimol Angsantikul, Brian T. Luk, Ashley V. Kroll, Yue Zhang and Yao Jiang and has published in prestigious journals such as Advanced Materials, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Xiaoli Wei

60 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle Functionalization

2017 640 citations Xiaoli Wei et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaoli Wei China	22	676	653	540	477	386	61	2.0k
José Luiz de Figueiredo United States	20	883 1.3×	673 1.0×	378 0.7×	680 1.4×	349 0.9×	44	2.5k
James O. Park United States	28	909 1.3×	722 1.1×	617 1.1×	205 0.4×	362 0.9×	92	2.6k
Amy Chang United States	13	738 1.1×	1.4k 2.2×	421 0.8×	460 1.0×	230 0.6×	28	2.3k
Aadil Khan United Kingdom	21	652 1.0×	1.1k 1.7×	553 1.0×	426 0.9×	531 1.4×	90	2.6k
Wei‐Wei Deng China	22	708 1.0×	829 1.3×	570 1.1×	849 1.8×	189 0.5×	51	2.1k
Yun Hu China	26	602 0.9×	343 0.5×	229 0.4×	391 0.8×	262 0.7×	100	1.6k
Xiaomeng Dai China	24	826 1.2×	644 1.0×	433 0.8×	466 1.0×	389 1.0×	54	1.9k
Kangshun Zhu China	30	510 0.8×	459 0.7×	571 1.1×	331 0.7×	288 0.7×	119	2.7k
Golnaz Morad United States	18	1.0k 1.5×	790 1.2×	406 0.8×	619 1.3×	284 0.7×	39	2.3k
Martina Rudelius Germany	24	595 0.9×	594 0.9×	264 0.5×	236 0.5×	225 0.6×	43	1.8k

Countries citing papers authored by Xiaoli Wei

Since Specialization

Citations

This map shows the geographic impact of Xiaoli Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoli Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoli Wei more than expected).

Fields of papers citing papers by Xiaoli Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoli Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoli Wei. The network helps show where Xiaoli Wei may publish in the future.

Co-authorship network of co-authors of Xiaoli Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoli Wei. A scholar is included among the top collaborators of Xiaoli Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoli Wei. Xiaoli Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Qiang, Yong Zhang, Shanshan Tian, et al.. (2025). Lachnospiraceae bacterium alleviates alcohol-associated liver disease by enhancing N-acetyl-glutamic acid levels and inhibiting ferroptosis through the KEAP1-NRF2 pathway. Gut Microbes. 17(1). 2517821–2517821. 3 indexed citations

Liu, Pei, Ang Zhao, Haiyuan Shen, et al.. (2025). Alcohol-induced disruption of hepatic m6A modification exacerbates alcohol-associated steatohepatitis by impairing liver immune microenvironment homeostasis. Hepatology. 83(4). 851–867. 2 indexed citations

Hou, Xianbin, Hailan Zhang, Wenjun Liu, et al.. (2024). Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China. Vaccine. 42(24). 126259–126259. 1 indexed citations

Xu, Rui‐Hua, Xiaoli Wei, Dongsheng Zhang, et al.. (2023). A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors.. Journal of Clinical Oncology. 41(4_suppl). 352–352. 27 indexed citations

Wei, Xiaoli, Furong Liu, Jihong Liu, et al.. (2022). First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors. Nature Communications. 13(1). 7012–7012. 13 indexed citations

Wei, Xiaoli, Qianwen Liu, Furong Liu, et al.. (2021). The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. OncoImmunology. 10(1). 1938381–1938381. 17 indexed citations

Wei, Xiaoli, Tianqi Luo, Jianing Li, et al.. (2021). Development and Validation of a Prognostic Classifier Based on Lipid Metabolism–Related Genes in Gastric Cancer. Frontiers in Molecular Biosciences. 8. 691143–691143. 22 indexed citations

Zhao, Hu, Xiaoli Wei, Yuqing Huang, et al.. (2021). 1329P A single-arm, open-label, multi-center, phase I study of HA121-28 in patients with advanced solid tumors. Annals of Oncology. 32. S1018–S1018. 3 indexed citations

Wei, Xiaoli, Chao Ren, Feng‐Hua Wang, et al.. (2020). A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors. Cancer Communications. 40(8). 345–354. 33 indexed citations

10.

Zhang, Yiyin, Yangyang Hu, Cui Ma, et al.. (2020). Diagnostic, Therapeutic Predictive, and Prognostic Value of Neutrophil Extracellular Traps in Patients With Gastric Adenocarcinoma. Frontiers in Oncology. 10. 1036–1036. 68 indexed citations

11.

Li, Xing, Fan Jiang, Hongxia Chen, et al.. (2020). Neuropeptide S attenuates methamphetamine-induced stereotyped behavior in rats. Biochemical and Biophysical Research Communications. 527(1). 98–103. 1 indexed citations

12.

Wang, Feng‐Hua, Xiaoli Wei, J. Feng, et al.. (2019). Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.. Journal of Clinical Oncology. 37(15_suppl). 6017–6017. 6 indexed citations

13.

Liu, Xiaoyan, Kai Yao, Yan Sun, et al.. (2019). HCN channel antagonist ZD7288 ameliorates neuropathic pain and associated depression. Brain Research. 1717. 204–213. 22 indexed citations

14.

Huang, Nana, Yiyin Zhang, Xiaoli Wei, et al.. (2019). MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells. Journal of Cancer. 10(4). 1039–1051. 29 indexed citations

15.

Qiu, Miao‐Zhen, Huijuan Qiu, Ying Jin, et al.. (2016). Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. Journal of Cancer. 7(6). 694–701. 11 indexed citations

16.

Wei, Xiaoli, Feng‐Hua Wang, Dongsheng Zhang, et al.. (2015). A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer. 15(1). 350–350. 140 indexed citations

17.

Qiu, Miao‐Zhen, Yixin Zhou, Xinke Zhang, et al.. (2014). Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 14(1). 823–823. 55 indexed citations

18.

Wei, Xiaoli, Miao‐Zhen Qiu, Huan‐Xin Lin, et al.. (2014). Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. PLoS ONE. 9(3). e89965–e89965. 18 indexed citations

19.

Li, Chong, Jie Shen, Xiaoli Wei, Cao Xie, & Weiyue Lu. (2012). Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy. Journal of drug targeting. 20(3). 264–271. 17 indexed citations

20.

Wang, Qingshan, Ní Hóng, Lan Lan, et al.. (2010). Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Research. 20(6). 701–712. 179 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact